Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Revista Colombiana de Cardiología
Print version ISSN 0120-5633
Abstract
RESTREPO, César A and CASTANO, Jesús A. Efficacy and safety of high-dose atorvastatin in patients with stage 5 chronic kidney disease on peritoneal dialysis therapy. Rev. Colomb. Cardiol. [online]. 2014, vol.21, n.6, pp.382-391. ISSN 0120-5633. https://doi.org/10.1016/j.rccar.2014.05.008.
Objective: To determine changes in lipid profile and safety of treatment with atorvastatin at high doses (greater than or equal to 40 mg/day) in patients with stage 5 chronic kidney disease. Patients, materials and methods: Patients with stage 5 chronic kidney disease in peritoneal dialysis therapy and hypercholesterolemia refractory to therapy with lovastatin at a dose of 40 mg daily and atorvastatin (less than 40 mg/day) that were assigned to atorvastatin therapy at high doses. Statistical analysis: A longitudinal study, retroprospective, correlational, single center with univariate and bivariate analysis. Results: Twenty met the inclusion criteria. Time with high-dose atorvastatin averaged 27 months. The average dose used 60.4 mg/day. The beneficial tendency to achieve therapeutic goals with time-varying was achieved in 65% of patients for total cholesterol, 50% LDL cholesterol, 40% non-HDL cholesterol and 45% for triglycerides. For variables LDL cholesterol and HDL cholesterol a statistically significant (p < 0.05) difference was found between the initial and final values. Twenty six complications were documented, none of them considered adverse events related to the administration of high-dose atorvastatin. Conclusions: In patients with stage 5 chronic kidney disease over 50 years, peritoneal dialysis therapy and hypercholesterolemia, high-dose atorvastatin achieved LDL levels get goals in 50% of patients without significant adverse events.
Keywords : Cholesterol; Statins; Hypercholesterolemia; Kidney.